Ma, Xiaosu
Liu, Rong
Pratt, Edward J.
Benson, Charles T.
Bhattachar, Shobha N.
Sloop, Kyle W.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist
https://doi.org/10.1007/s13300-024-01554-1
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 20 December 2023
Accepted: 9 February 2024
First Online: 24 February 2024
Declarations
:
: Xiaosu Ma, Rong Liu, Edward J. Pratt, Charles T. Benson, Shobha N. Bhattachar, and Kyle W. Sloop are employees and shareholders of Eli Lilly and Company, Indianapolis, USA.
: Study protocols and informed consent forms were approved by an ethics review board at each site (study A: ERB Midlands IRB, KS 66212, USA; study B: National Healthcare Group Domain Specific Review Board, Singapore 138543). The study was conducted in accordance with ethical principles of ICH GCP and the Declaration of Helsinki of 1964, and its later amendments. Written informed consent was obtained from each patient at study entry before any study procedures.